[In vitro hepatic targeting tendency of galactosyl-anti CD3 McAb-TILS].
This study was undertaken to enhance the hepatic targeting tendency of tumor infiltrating lymphocytes (TILs) and hence to lower the recurrence rate of primary liver cancer after hepatectomy. Galactosyl-anti CD3McAb-TILs were prepared and then were incubated together with hepatocytes. Their interaction through asialoglycoprotein receptor-mediated mechanism was observed under the inverted phase contrast microscope. The carbohydrate density of galactosyl-anti CD3McAb and the combining rate of galactosyl-anti CD3McAb with TILs were measured. The results revealed that galactosyl-anti CD3 McAb-TIL obviously were adhered to hepatocytes. The carbohydrate density of galactosyl-anti CD3McAb was 62.18, and the combining rate of galactosyl-anti CD3McAb with TILs was 97.9%. The results suggested that in vitro hepatic targeting tendency of galactosyl-anti CD3McAb-TILs was satisfactory, and that the carbohydrate density of 62.18 and the combining rate of 97.9% ensured the effective use of TILs.
Department of General Surgery, First Affiliated Hospital, WCUMS, Chengdu 610041.
P
P
Jiang
S
S
He
C
C
Zhang
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D037263:Asialoglycoprotein Receptor / Q000378:metabolism; D017252:CD3 Complex / Q000276:immunology*; D002469:Cell Separation; D005260:Female; D038983:Galactolipids / Q000276:immunology*; D000922:Immunotoxins / Q000493:pharmacokinetics*; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D008114:Liver Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008297:Male; D051379:Mice
D000911:Antibodies, Monoclonal; D037263:Asialoglycoprotein Receptor; D017252:CD3 Complex; D038983:Galactolipids; D000922:Immunotoxins; C008543:galactosylglyceride